Device Trial Radar · NCT03719885
TrueTear in Sjogren's Disease Patients
Last checked: Nov 20, 2026Latest source record: Jul 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Dec 1, 2018
Primary completion
Apr 25, 2019
Study completion Dec 31, 2019
Sponsor
- Lead sponsor
- University of PennsylvaniaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Allergan
- First posted
- Oct 25, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate acute tear production produced by the intranasal tear neurostimulator in participants with Sjögrens syndrome and aqueous tear deficiency. Our primary goal is to evaluate whether Sjögrens patients respond to this intervention and whether there is a baseline tear production level below which these patients do not respond.
Conditions
- Dry Eye Syndromes
- Sjogren's Syndrome
Interventions
TrueTear Intranasal Tear NeurostimulatorDevice
This study will evaluate the immediate tear production resulting from use of intranasal tear neurostimulation in patients with Sjogren's disease
Primary outcomes
What the sponsor says the trial is designed to measure.
- Schirmer TestingTime frame: Immediately following the procedure (ie immediately following use of the device)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Scheie Eye Institute, University of Pennsylvania
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.